The Effect of Virtual Reality and Eye Mask During Dressing After CABG Surgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorIstanbul University - Cerrahpasa

About this trial

This study aims to evaluate the effects of virtual reality (VR) and eye mask (EM) applications on pain, anxiety, and physiological parameters during dressing after Coronary Artery Bypass Graft (CABG) surgery.

Postoperative dressing procedures, especially after sternotomy, often cause significant pain and anxiety in patients. These issues can negatively impact recovery and increase the need for medication. Non-pharmacological interventions such as VR and EM may help reduce these symptoms.

In this randomized controlled trial, 90 patients are divided into three groups: VR group, EM group, and a control group receiving standard care. Pain and anxiety levels are monitored baseline, immediately after, and 15 minutes after both the first and second dressing procedures. Physiological parameters are measured baseline, during, immediately after, and 15 minutes after both dressing procedures. Additionally, analgesic use is followed baseline and immediately after each dressing procedure. The study is conducted in a cardiovascular intensive care unit in Istanbul, Türkiye. It is expected that the findings will support the integration of VR and EM as effective, low-cost, and non-invasive options for postoperative care, improving patient comfort and healthcare quality.

Eligibility criteria

Qualifiers

Adults aged 18-65 years

First-time coronary artery bypass graft (CABG) surgery for coronary artery disease

ASA physical status I, II, or III

Conscious, oriented, and cooperative

Disqualifiers

Presence of sternal wound infection or inflammation

Intubated at the time of assessment

Undergoing revision surgery

Receiving anesthesia or sedation in the ICU

Trial design

Treatments tested in this trial

  • Virtual Reality Headset
  • Eye Mask

Treatment groups

90 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Istanbul University - Cerrahpasa

Lead sponsor

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Collaborator